SCPH scPharmaceuticals, Inc.: Enterprise Value to EBITDA Ratio
The EV/EBITDA price chart for scPharmaceuticals Inc. (SCPH) on GURU.Markets is . scPharmaceuticals Inc. (SCPH) automates the creation of injections using algorithms, although medical supervision remains with humans. The business is implementing the Furoscix system for home treatment of heart failure, reducing clinic costs. This unique product allows for the effective displacement of hospital therapy, ensuring high margins and protection against cheap generics.
Comprehensive metric breakdowns and analytics for scpharmaceuticals.com (SCPH)
- market price and analyst price targets:
- company stock capitalization data:
- business book valuation details:
- debt obligations and liquidity statistics:
Debt to Equity scPharmaceuticals Inc.|SCPH - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity scPharmaceuticals|SCPH - Company Total Debt Obligations|Debts to Book Capitalization scPharmaceuticals Inc.|SCPH - Company Long-Term Liabilities|Company Short-Term Debt scPharmaceuticals|Quick Ratio scpharmaceuticals.com
- financial results and valuation multiples details:
SCPH - Final Profit|Projected Future Earnings scPharmaceuticals Inc.|SCPH - P/E Multiple|Future Price to Earnings scPharmaceuticals|SCPH - Growth-Adjusted Payback Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization scPharmaceuticals Inc.|SCPH - Operating profit before deduction of amortization|Net earnings per share (EPS TTM) scPharmaceuticals|SCPH - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth scpharmaceuticals.com|SCPH - Net earnings per share growth this year|Earnings growth forecast for next year scPharmaceuticals Inc.
Comprehensive company analysis:scPharma SCPH
Supply chain disruptions in electronics and component logistics for scPharmaceuticals Inc. therapies make operational efficiency critical. This metric compares the business value, including net debt, against earnings before interest, taxes, depreciation, and amortization. By analyzing the historical EV/EBITDA trajectory, an investor determines the asset's payback period excluding tax effects. This indicator helps identify stock overvaluation relative to the company's actual ability to generate cash flow.
Competitors of scPharmaceuticals Inc. (SCPH)
Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Haleon Group HLN|Kenvue Health (KVUE) - Company Value to EBITDA|VRNA: Enterprise Value to EBITDA Ratio|jyongbio.com - Enterprise Value to Operating Income Before Depreciation Ratio|LGND: EV/EBITDA Multiple|Amneal Pharmaceuticals, Inc. - Business Value to Operating Income Before Depreciation|PRGO (Perrigo Company) - EV/EBITDA Multiple|Company Value to EBITDA Alvotech Biopharmaceuticals ALVO|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Liquidia Corporation (LQDA)|GLPG (glpg.com) - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization ANI Pharmaceuticals, Inc. ANIP|Total Company Value to Operating Income Before Depreciation Ratio MannKind Corp (MNKD)|Amphastar - EV/EBITDA Multiple|Pacira Corp (PCRX) - Enterprise Value to EBITDA Ratio|ARS Pharmaceuticals (SPRY) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio TBPH (theravance.com)|AQST (Aquestive Therapeutics, Inc.) - EV/EBITDA Multiple|TECX: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple TNXP|EV/EBITDA Multiple sxtchina.com (SXTC)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Eupraxia Pharmaceuticals Inc. EPRX|Business Value to Operating Income Before Depreciation BHST|EXOZ - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Oramed Pharmaceuticals (ORMP) - Enterprise Value to EBITDA Ratio|ENTX: EV/EBITDA Multiple|MindWalk Therapeutics (HYFT) - EV/EBITDA Multiple|ABVC (ABVC BioPharma) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio cumberlandpharma.com (CPIX)|EV/EBITDA Multiple QNTM|FGEN - Company Value to EBITDA|Telomir Pharma - Enterprise Value to EBITDA Ratio|EV/EBITDA Multiple Rani Therapeutics Holdings RANI|SNYR: Enterprise Value to EBITDA Ratio|Rallybio Corporation - Enterprise Value to Operating Income Before Depreciation Ratio|LEXX: EV/EBITDA Multiple|PULM - Total Company Value to Operating Income Before Depreciation Ratio|PTHL (Pheton Holdings Limited) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio Aptorum (APM)|EV/EBITDA Multiple LYRA|EV/EBITDA Multiple impactbiomedinc.com (IBO)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization TNF Pharmaceuticals, Inc. TNFA|cbdMD Inc. - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|PRFX - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Total Company Value to Operating Income Before Depreciation Ratio Altamira Therapeutics CYTO|LIPO (Lipella Pharmaceuticals) - Enterprise Value to EBITDA Ratio|optinose.com - Business Value to Operating Income Before Depreciation|PIRS (Pieris Pharmaceuticals, Inc.) - EV/EBITDA Multiple|Procaps Group (PROC) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Petros (PTPI)|Qilian International Corp - Enterprise Value to Operating Income Before Depreciation|EV/EBITDA Multiple SLRN (Acelyrin, Inc.)|TFFP - Enterprise Value to EBITDA Ratio
